Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 4, Issue 5, 1997, Pages 325-331

  Garson, J A ^a   Uhnoo, I ^b   Whitby, K ^a   Braconier, J H ^c   Deaville, R ^a   Duberg, A ^d   Wallmark, E ^c   Wistrom J ^e   Goldin, R D ^f   Spacey, B ^g  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Medical Centre Hospital   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Genotype; Hepatitis C; Histology; Lymphoblastoid interferon; PCR

Indexed keywords

ALPHA INTERFERON; VIRUS RNA;

ADULT; ARTICLE; BIOPSY; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LIVER; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SWEDEN; VIROLOGY;

ADULT; BIOPSY; COHORT STUDIES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; SWEDEN;

EID: 0031225290     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00061.x     Document Type: Article

References (22)

1. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
2. Brillanti S, Garson JA, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.
3. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192-199.
4. Hino K, Sainokami S, Shimoda K et al. Genotypes and titers for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299-305.
5. Garson JA, Brillanti S, Whitby K et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995; 45: 348-353.
6. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
7. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
8. Brand CM, Leadbetter L, Budiman R, Lechner K, Gisslinger H. Successful treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon alpha N1 and in-vitro studies on the specificity of the antibodies. Br J Haematol 1994; 86: 216-218.
9. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
10. Garson JA, Ring C, Tuke P, Tedder RS. Enhanced detection by PCR of hepatitis C virus RNA. Lancet 1990; 336: 878-879.
11. Whitby K, Garson JA. Optimisation and evaluation of a quantitative chemiluminescent polymerase chain reaction assay for hepatitis C virus RNA. J Virol Methods 1995; 51: 75-88.
12. Davis GL. Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 1990; 11 (suppl 1): S72-S77.
13. Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-alpha on alanine aminotransferase in patients with chronic hepatitis-C or chronic non-a non-b-hepatitis - a metaanalysis. Clin Drug Invest 1995; 9: 239-254.
14. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato BA. Interferon-alpha treatment in patients with chronic hepatitis C - a metaanalytic evaluation. Clin Drug Invest 1995; 9: 141-149.
15. Bacon BR, Farrell G, Benhamou JP et al. Lymphoblastoid interferon improves long-term response to a 6-month course of treatment when compared with recombinant interferon-alpha-2b - results of an international trial. Hepatology 1995; 22: 181.
16. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882-885.
17. Brillanti S, Garson JA, Tuke PW et al. Effect of alpha interferon therapy on hepatitis C viraemia in community acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J Med Virol 1991; 34: 136-141.
18. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viraemia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks. Hepatology 1994; 19: 280-285.
19. Shev S, Widell A, Foberg U et al. HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile. Infection 1995; 23: 253-257.
20. Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995; 27: 325-329.
21. Schvarcz R, Yun ZB, Sonnerberg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-47.
22. Lin R, Roach E, Zimmerman M, Strasser S, Farell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995; 23: 487-496.